Recruiting
Ketamine maintenance treatment for depression: A multicenter open-label randomized controlled trial (PreKET)
2025-521330-29-00· Phase 2· Ostfold Hospital Trust· Source
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?
2026-525513-31-00· Phase 3· Norges Teknisk-Naturvitenskapelige Universitet NTNU· Source
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270· Phase 3· Genmab· Source
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB® versus Riluzole in participants with Amyotrophic Lateral Sclerosis
2024-513927-18-00· Phase 2· Oslo University Hospital HF· Source
Recruiting
Comprehensive Evaluation of Two Second-Line Therapeutic Approaches for Immune Thrombocytopenia (ITP) – a Pragmatic Randomized Controlled Trial - Holistic Study
2023-505573-32-00· Phase 3· Ostfold Hospital Trust· Source
Recruiting
The Nordic Chronic Migraine Trial of CGRP monoclonal antibody and onabotulinumtoxin A dual therapy – a randomized-controlled double-blind trial (NorMig)
2024-517981-40-00· Phase 3· Oslo University Hospital HF· Source
Recruiting
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
NCT06929806· Phase 3· Pharmacosmos A/S· Source
Recruiting
Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
2024-511346-39-00· Phase 1· Chugai Pharmaceutical Co. Ltd.· Source
Recruiting
Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated glioblastoma (IDHwt) patients +/- tumor treating fields (Optune)
2023-506998-35-00· Phase 3· Vaestra Goetalandsregionen· Source
Recruiting
Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
NCT06488482· Phase 3· Uppsala University· Source
Active, not recruiting
Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcutaneous TNF inhibitor:
The Rheumatoid Arthritis therapeutic DRUg Monitoring trial (RA-DRUM)
2023-510184-35-00· Phase 4· Diakonhjemmet Sykehus AS· Source
Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417· Phase 1· Chugai Pharmaceutical· Source
Active, not recruiting
Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841)
2022-500100-21-01· Phase 2· Oslo University Hospital Hf· Source
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· Phase 3· GlaxoSmithKline· Source
Recruiting
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)
2022-500587-35-01· Phase 3· University Of Nottingham· Source
Recruiting
Efficacy of Hyperbaric oxygen in addition to standard treatment for acute
sudden deafness
2024-510798-84-00· Phase 2/3· Helse Bergen HF· Source
Active, not recruiting
Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with extensive stage small-cell lung cancer?
NCT05223647· Phase 3· Norwegian University Of Science And Technolology· Source
Active, not recruiting
Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer
NCT04742075· Phase 2· Nordic Society of Gynaecological Oncology - Clinical Trials Unit· Source
Active, not recruiting
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04736706· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421· Phase 3· Pfizer· Source
Active, not recruiting
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease
NCT04578639· Phase 3· Haukeland University Hospital· Source
Recruiting
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
NCT04513639· Phase 2/3· Oslo University Hospital· Source
Recruiting
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
NCT03903835· Phase 3· Karolinska Institutet· Source
Active, not recruiting
Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer
NCT03540420· Phase 2· Norwegian University of Science and Technology· Source
Active, not recruiting
Phase III Radium 223 mCRPC-PEACE III
NCT02194842· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source